Trial · NCT07883837
Platelet Rich Plasma Versus Mitomycin C Injection Following Visual Internal Urethrotomy in Urethral Stricture
NCT07883837, Phase 3, Completed, Ain Shams University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Platelet Rich Plasma Versus Mitomycin C Injection Following Visual Internal Urethrotomy in Urethral Stricture. Trials, record NCT07883837. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883837
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Platelet Rich Plasma Versus Mitomycin C Injection Following Visual Internal Urethrotomy in Urethral Stricture
- NCT number
- NCT07883837
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 50 participants, actual
- Lead sponsor
- Ain Shams University
- Conditions
- Urethral Stricture
- Interventions
- Visual internal urethrotomy followed by submucosal intralesional mitomycin C injection, Visual internal urethrotomy followed by submucosal Platlet Rich Plasma injection
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical effectiveness in improving patient-reported lower urinary tract symptoms according to the International Prostate Symptom Score | At 3 months and 6 months after surgery | This outcome measure assessed the degree of improvement in lower urinary tract symptoms reported by patients after the intervention. The International Prostate Symptom Score is a validated, patient-reported questionnaire consisting of seven questions that evaluate the severity of urinary symptoms, including incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Each question is scored from 0 to 5, giving a total score range of 0 to 35, where scores of 1 to 7 indicate mild symptoms, 8 to 19 indicate moderate symptoms, and 20 to 35 indicate severe symptoms. |
| Primary | Clinical effectiveness in improving patient's uroflometry | At 3 months and 6 months after surgery | This outcome assessed urinary flow using uroflowmetry, a non-invasive test measuring the rate and pattern of urine flow.It records average and maximum urinary flow rates in milliliters per second. These values were compared between both groups to determine whether either treatment produced greater improvement. A maximum flow rate above 10 mL per second was considered successful, while a value below 10 mL per second was considered suspicious for recurrence and prompted further evaluation with retrograde cystourethrography. |
| Secondary | Quality of Life Assessment | At 3 months and 6 months after surgery | This outcome assessed the impact of urinary symptoms on patients' daily lives using the quality of life question from the International Prostate Symptom Score questionnaire. Patients were asked how they would feel if they had to spend the rest of their lives with their current urinary condition, with responses ranging from delighted to terrible on a scale of 0 to 6. |
| Secondary | Post-void residual urine volume | At 3 months and 6 months after surgery | This outcome assessed bladder emptying by measuring the amount of urine remaining in the bladder after voiding, using pelvi-abdominal ultrasound. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883837
GET https://conductscience.org/api/trials/v1/NCT07883837/registered